Arbutus Biopharma Corp (NASDAQ:ABUS) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 1,682,416 shares,
a decline of 31.2%
from the August 15th total of 2,445,318 shares. Currently, 5.0% of the shares of the company are short sold. Based on an average daily volume of 181,110 shares, the short-interest ratio is currently 9.3 days.
A number of hedge funds and other institutional investors have recently modified their holdings of ABUS.
BlackRock Inc. raised its holdings in Arbutus Biopharma by 246.6% in the 2nd quarter.
BlackRock Inc. now owns 2,391,143 shares of the biopharmaceutical company’s stock valued at $17,455,000 after buying an additional 1,701,237 shares during the last quarter.
Foresite Capital Management IV LLC raised its holdings in Arbutus Biopharma by 886.3% in the 1st quarter. Foresite Capital Management IV LLC now owns 1,485,245 shares of the biopharmaceutical company’s stock valued at $7,426,000 after buying an additional 1,334,653 shares during the last quarter.
Bank of Montreal Can acquired a new stake in Arbutus Biopharma during the 2nd quarter valued at approximately $6,897,000.
Northern Trust Corp acquired a new stake in Arbutus Biopharma during the 2nd quarter valued at approximately $2,164,000.
Finally, Bank of New York Mellon Corp acquired a new stake in Arbutus Biopharma during the 2nd quarter valued at approximately $609,000. Institutional investors and hedge funds own 40.05% of the company’s stock.
WARMINSTER, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the
Chardan Genetic Medicines Conference on Tuesday, October 9, 2018
at 2:45 pm – 3:10 pm ET in New York.